Vol. 50 | No. 1 | January-June 2022 Back

Open Access

Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-analysis of Randomized Controlled Trials

Glein M. Sayat, Ferdinand R. Gerodias Jr, Lea Arceli D. Gonzales Porciuncula
Jun 2022 DOI 10.69944/pjc.4580ffc182

Abstract

INTRODUCTION: After transcatheter aortic valve replacement (TAVR), ischemic/embolic complications and bleeding remain important because it correlates with mortality. The optimal antithrombotic regimen after successful TAVR remains unclear. This study compared the efficacy and safety of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) among post-TAVR patients. 

METHODS: Extensive search of PubMed, MEDLINE, Cochrane, and Ovid was done for articles published until November 20, 2020. Studies were limited to randomized controlled trials. Outcome measures include stroke, myocardial infarction (MI), all-cause mortality, and major bleeding. Two reviewers independently reviewed the studies. Results were gathered from published articles, journals, and clinical trials. Studies were critically appraised with regard to methods of minimizing bias. All four studies included received a quality scale for meta-analysis overall score of not less than B. Statistical analysis was done using Review Manager V5.4. 

RESULTS: Four randomized controlled trials with 1086 patients were included in this meta-analysis. Overall, the risk of stroke (odds ratio [OR], 0.94 [0.54–1.64]), MI (OR, 0.50 [0.18–1.40]), and overall mortality (OR, 1.01 [0.65–1.57]) did not differ significantly between DAPT and SAPT. There was increased risk of bleeding noted with DAPT, thus favoring SAPT (OR, 0.44 [0.30–0.65]). 

CONCLUSION: Among patients who underwent TAVR, DAPT compared with SAPT had similar rates of stroke, MI, and death. Because of lower rates of bleeding, we recommend using single antiplatelet therapy after TAVR. 

KEYWORDS: TAVR, TAVI, antiplatelet, single antiplatelet therapy, antithrombotic, DAPT

References
  1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006–3008.
  2. Gargiulo G, Collet JP, Valgimigli M. Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention 2015;11(suppl W):W92–W95.doi:10.4244/EIJV11SWA28.
  3. Capodanno D, Angiolillo DJ. Antithrombotic therapy for prevention of cerebral thromboembolic events after transcatheter aortic valve replacement: evolving paradigms and ongoing directions. JACC Cardiovasc Interv 2017;10:1366–1369. doi: 10.1016/j.jcin.2017.05.005.
  4. Raheja H, Garg A, Goel S, et al. Comparison of single versus dual antiplatelet therapy after TAVR: a systematic review and meta-analysis [published online March 8, 2018]. Catheter Cardiovasc Interv 2018;92(4):783-791. doi: 10.1002/ccd.27582. PMID: 29516608.
  5. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011;108:1772–1776.
  6. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014;174:624–627.
  7. Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin1 Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357–1365.
  8. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation [published online August 30, 2020]. N Engl J Med 2020;383(15):1447-1457. doi: 10.1056/ NEJMoa2017815. PMID: 32865376.
  9. Baumgartner H, Falk V, Bax JJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739–2791. doi: 10.1093/eurheartj/ehx391.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.